$1.70
-0.08-4.49%
At Close: -
$1.65
-0.05-2.69%
After Hours: Jul 19, 6:38 PM EDT
15 minutes delayed
Comments
Loading...
BioAtla
BCABNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
BioAtla (NASDAQ:BCAB) Stock, Analyst Ratings, Price Targets, Forecasts
BioAtla Inc has a consensus price target of $13.14 based on the ratings of 7 analysts. The high is $25 issued by EF Hutton on August 2, 2023. The low is $5 issued by JMP Securities on May 23, 2024. The 3 most-recent analyst ratings were released by JMP Securities, HC Wainwright & Co., and JMP Securities on May 23, 2024, May 15, 2024, and March 28, 2024, respectively. With an average price target of $8 between JMP Securities, HC Wainwright & Co., and JMP Securities, there's an implied 383.62% upside for BioAtla Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
HC Wainwright & Co.
JP Morgan
EF Hutton
BTIG
1calculated from analyst ratings
Analyst Ratings for BioAtla
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/23/2024 | Buy Now | 202.26% | JMP Securities | Reni Benjamin | $12 → $5 | Maintains | Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | 323.17% | HC Wainwright & Co. | Arthur He | → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 625.43% | JMP Securities | Reni Benjamin | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/27/2024 | Buy Now | 323.17% | HC Wainwright & Co. | Arthur He | $10 → $7 | Maintains | Buy | Get Alert |
| 12/05/2023 | Buy Now | 625.43% | JMP Securities | Reni Benjamin | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/08/2023 | Buy Now | 504.52% | HC Wainwright & Co. | Arthur He | $17 → $10 | Maintains | Buy | Get Alert |
| 09/25/2023 | Buy Now | 746.33% | JP Morgan | Brian Cheng | $17 → $14 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 927.69% | JP Morgan | Brian Cheng | $19 → $17 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 625.43% | JMP Securities | Reni Benjamin | → $12 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/02/2023 | Buy Now | 1411.3% | EF Hutton | Tony Butler | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 927.69% | HC Wainwright & Co. | Arthur He | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 625.43% | JMP Securities | Reni Benjamin | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | 927.69% | HC Wainwright & Co. | Arthur He | → $17 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 1411.3% | EF Hutton | Tony Butler | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2023 | Buy Now | 1411.3% | EF Hutton | Tony Butler | → $25 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | 1048.59% | JP Morgan | Brian Cheng | $23 → $19 | Maintains | Overweight | Get Alert |
| 03/28/2023 | Buy Now | 685.88% | BTIG | Thomas Shrader | $68 → $13 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | 625.43% | JMP Securities | Reni Benjamin | $17 → $12 | Maintains | Outperform | Get Alert |
| 03/24/2023 | Buy Now | 383.62% | Credit Suisse | Tiago Fauth | → $8 | Reiterates | → Neutral | Get Alert |
| 03/24/2023 | Buy Now | 1411.3% | EF Hutton | Tony Butler | → $25 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | 927.69% | HC Wainwright & Co. | Arthur He | $20 → $17 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 1411.3% | EF Hutton | Tony Butler | → $25 | Initiates | → Buy | Get Alert |
| 11/04/2022 | Buy Now | 383.62% | Credit Suisse | Tiago Fauth | $4 → $8 | Maintains | Neutral | Get Alert |
| 09/15/2022 | Buy Now | 927.69% | JMP Securities | Reni Benjamin | → $17 | Initiates | → Market Outperform | Get Alert |
| 08/10/2022 | Buy Now | 141.81% | Credit Suisse | Tiago Fauth | $5 → $4 | Maintains | Neutral | Get Alert |
| 08/10/2022 | Buy Now | 1109.04% | HC Wainwright & Co. | Swayampakula Ramakanth | $25 → $20 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 202.26% | Credit Suisse | Tiago Fauth | $35 → $5 | Downgrade | Outperform → Neutral | Get Alert |
| 03/21/2022 | Buy Now | 1411.3% | HC Wainwright & Co. | Swayampakula Ramakanth | → $25 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for BioAtla (BCAB) stock?
The latest price target for BioAtla (NASDAQ:BCAB) was reported by JMP Securities on May 23, 2024. The analyst firm set a price target for $5.00 expecting BCAB to rise to within 12 months (a possible 202.26% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioAtla (BCAB)?
The latest analyst rating for BioAtla (NASDAQ:BCAB) was provided by JMP Securities, and BioAtla maintained their market outperform rating.
When was the last upgrade for BioAtla (BCAB)?
There is no last upgrade for BioAtla
When was the last downgrade for BioAtla (BCAB)?
The last downgrade for BioAtla Inc happened on May 5, 2022 when Credit Suisse changed their price target from $35 to $5 for BioAtla Inc.
When is the next analyst rating going to be posted or updated for BioAtla (BCAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioAtla, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioAtla was filed on May 23, 2024 so you should expect the next rating to be made available sometime around May 23, 2025.
Is the Analyst Rating BioAtla (BCAB) correct?
While ratings are subjective and will change, the latest BioAtla (BCAB) rating was a maintained with a price target of $12.00 to $5.00. The current price BioAtla (BCAB) is trading at is $1.65, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.